Trials / Conditions / Adult Acute Promyelocytic Leukemia (M3)

Adult Acute Promyelocytic Leukemia (M3)

18 registered clinical trials studyying Adult Acute Promyelocytic Leukemia (M3).

Status	Trial	Sponsor	Phase
Completed	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015	City of Hope Medical Center	Phase 1
Withdrawn	Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia NCT01548911	Wake Forest University Health Sciences	Phase 2
Terminated	Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission NCT01465386	Fred Hutchinson Cancer Center	Phase 2
Completed	Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Pr NCT01031368	Nohla Therapeutics, Inc.	Phase 1
Completed	Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia NCT01146223	Children's Oncology Group	—
Completed	Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia NCT00588809	National Cancer Institute (NCI)	Phase 2
Completed	Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00602225	University of Washington	Phase 1 / Phase 2
Completed	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrom NCT00331513	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat in Treating Patients With Acute Myeloid Leukemia NCT00305773	National Cancer Institute (NCI)	Phase 2
Completed	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic NCT00301938	National Cancer Institute (NCI)	Phase 1
Completed	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826	National Cancer Institute (NCI)	Phase 1
Completed	Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT00062075	National Cancer Institute (NCI)	Phase 2
Completed	BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia NCT00006213	National Cancer Institute (NCI)	Phase 1
Completed	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, NCT00005064	National Cancer Institute (NCI)	Phase 1
Completed	Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin W NCT00003934	National Cancer Institute (NCI)	Phase 3
Completed	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371	Case Comprehensive Cancer Center	Phase 2
Approved For Marketing	Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyel NCT01869803	Wake Forest University Health Sciences	—